

Autumn Conference KeplerCheuvreux Paris, 16th September 2015

Thierry Lemonnier, CFO



ARKEMA TODAY



- Entrepreneurial culture
- Balanced global footprint
- Technology leaderships
- Strong innovation pipeline

- Strong focus on partnerships and relations with customers
- Competitive world-scale units on 3 continents
- Highly skilled and committed management team
- Leading positions by segment (#1 to #3 WW)





OUR PORTFOLIO



Business with growth above GDP attracting more investments

Business primarily focused on cash generation



1H'15 SALES BREAKDOWN BY SEGMENT AND REGION



Favorable balance in current market conditions









Bostik	 Strong performance Confirm its very promising start within Arkema 	
Thiochemicals in Malaysia	 Excellent technical and commercial start-up of the unit Significant contribution with ramp-up a touch faster than initially planned 	
Acrylics	 Continue to be in low-cycle conditions in the continuity of 1Q'15 Quite limited contribution from Sunke 	
Specialty polyamides	1H'15 above 1H'14 with good margin % level	
Fluorogases	 Confirmation of gradual improvement of pricing of some gases Some benefits from productivity initiatives 	
Disposal program	Project to divest Sunclear (€180 m sales, €105 m EV). Information - consultation process of work councils in France finalized	
Operational excellence	PMMA: project* to shutdown the production of extruded sheets at Bernouville (France) entailing a loss of 38 positions	

* Subject to the information - consultation process of works councils in France



BOSTIK'S HIGHLIGHTS

1H'15 performance (of which 5 months inside Arkema)	 Strong performance which supports decision to acquire Bostik EBITDA of €89 m over 6m'15 (of which 5 months inside Arkema) Up +15% versus 6m'14 EBITDA margin close to 11% 	
Smooth integration	 Highly committed teams Implementation of synergies well on track with short-term focus on cost gains Benefits from synergies to ramp up over next quarters according to plans 	
Purchase Price Allocation (PPA) impact in 2Q'15*	 €(52) m charges booked in "other income and expenses" €(36) m inventory step-up €(16) m additional depreciation on tangible and intangible asset +€76 m tax profit +€60 m deferred tax assets recognized in France +€16 m reversal of deferred tax liabilities 	

* Provisional accounting



IN €M (EXCEPT EPS)	2Q'14*	2Q'15	VARIATION
Sales	1,520	2,106	+38.6%
EBITDA	210	320	+52.4%
EBITDA margin	13.8%	15.2%	
Recurring operating income	130	208	+60.0%
Adjusted net income	72	120	+66.7%
Net income (Group share)	50	133	+166.0%
Adjusted EPS** (euro)	1.09	1.65	+51.4%

* Restated figures in accordance with IFRIC 21 "Levies"

** For 2014, the adjusted EPS was adjusted to take account of the share capital increase with preferential subscription rights finalized in December 2014



2Q'15 SALES BRIDGE





HIGH PERFORMANCE MATERIALS

2Q'15 KEY FIGURES 2Q'14* 2Q'15 variation

20211	2013	variación
427	907	+112.4%
76	149	+96.1%
17.8%	16. 4%	
52	111	+113.5%
	427 76 17.8%	76 149 17.8% 16.4%

2Q'15 SALES DEVELOPMENT

Volumes	+2.7%
Prices	+0.6%
Currency	+9.1%
Scope	+99.7%

2Q'15 HIGHLIGHTS

<u>Bostik</u>

In €m

- ▶ €418 m sales
- Performance significantly up YoY supported by successful implementation of strategy

Technical Polymers

- Improved performance in polyamide 12 vs 2Q'14 which was impacted by a large maintenance turnaround in Mont (France)
- Benefit from growing applications (batteries, electronics) offsetting lower demand in some oil and gas applications

Performance Additives

 Good performance supported by specialty molecular sieves for petrochemicals

2Q'15 SALES BY BUSINESS LINE





INDUSTRIAL SPECIALTIES

2Q'15 KEY FIGURES

	•		
In €m	2Q'14*	2Q'15	variation
Sales	583	684	+17.3%
EBITDA	85	128	+50.6%
EBITDA margin	14.6%	1 8.7 %	
Rec. operating income	52	84	+61.5%

2Q'15 SALES DEVELOPMENT

Volumes	+2.3%
Prices	+2.9%
Currency	+11.2%
Scope	+0.9%

2Q'15 HIGHLIGHTS

Thiochemicals

- Excellent performance supported by significant contribution from the new platform in Malaysia
- Ramp-up of Malaysian plant a touch faster than initially planned with strong demand in Asia in the animal nutrition market

Fluorogases

 Gradual improvement reflecting higher prices of some fluorogases and productivity initiatives

PMMA

 Very good level of results with continuing favorable environment in MMA

Hydrogen Peroxide

Results up YoY with good developments in specialties

·

2Q'15 SALES BY BUSINESS LINE





11 * Restated figures in accordance with IFRIC 21 "Levies" and new reporting

COATING SOLUTIONS

2Q'15 KEY FIGURES

In €m	2Q'14*	2Q'15	variation
Sales	505	509	+0.8%
EBITDA	61	61	-
EBITDA margin	1 2. 1%	12.0%	
Rec. operating income	39	32	(17.9)%

2Q'15 SALES DEVELOPMENT

Volumes	+0.6%
Prices	(13.3)%
Currency	+10.1%
Scope	+3.4%

2Q'15 HIGHLIGHTS

Acrylics (acid + esters)

- ▶ Unit margins at cyclical low
 - Significantly down YoY
 - In the continuity of 1Q'15
 - Expected to remain so throughout 2015
- ▶ Quite limited contribution from Sunke
 - Market situation expected to persist for the remainder of 2015

Coating Resins and Additives

- Solid performance supported by:
 - New developments at Coatex
 - Actions to improve profitability in coating resins
- Ongoing soft demand in decorative paints and construction in Europe







12 * Restated figures in accordance with IFRIC 21 "Levies" and new reporting

IN €M	2Q'15	
EBITDA	320	
Working capital variation*	(28)	Excluding €27 m non-recurring items primarily relating to Bostik acquisition
Taxes	(63)	 Current taxes excluding impact of Bostik PPA
Cost of debt	(22)	
Capex**	(86)	2015e capex: ~ €450m computed with the 1.25 €/US\$ rate used for the budget. Will need to be adjusted depending on currency variations. A 10-cent variation in €/US\$ implies close to €15m change in capex
Others	(5)	
RECURRING CASH FLOW	116	
Non-recurring items in operating and investing cash flow	(11)	 Mainly restructuring expenses
FREE CASH FLOW	105	
Impact of portfolio management	(1)	
NET CASH FLOW	104	

* Variation in working capital and fixed asset payables excluding non-recurring items

** Excluding capital expenditure related to M&A







- Standard & Poor's: BBB (negative outlook)
- Moody's: Baa2 (negative outlook)



- Debt duration*: 6 years
- Average interest rate on bonds*: ~3% / year
- ► Cash cost of debt: ~€55 m / year
- Cash cost of hybrid (4.75% / year): ~€33 m / year

* Excluding hybrid bond

2015 OUTLOOK

Macro-economic assumptions

- Arkema enters 2H'15 with confidence, while remaining cautious on the future development of the global economic environment
- Market conditions expected to remain volatile and contrasted with different dynamics depending on geographic regions and end-markets
- ► Trends in FX rates (mainly US\$/€) expected to remain favorable versus last year, albeit with a more limited benefit in 2H than in 1H
- Unit margins in acrylic monomers expected to remain at low-cycle levels

2015 main drivers

- Consolidation of Bostik on 11 months
- Ramp-up of the new Thiochemicals platform in Malaysia
- Gradual improvement of fluorogas business
- Operational excellence initiatives to offset part of the inflation on fixed costs
- Contribution from Sunke should remain well below expectations given current market conditions in acrylics in Asia

Based on these drivers, assuming a continuity in current market conditions, and given the usual seasonality of the second half of the year, Arkema expects an EBITDA slightly above €1 billion (including Bostik contribution) in 2015



LONG-TERM AMBITION



OUR LONG-TERM AMBITION



Defined in normalized market conditions (Acrylics in mid-cycle, €/US\$ at 1.15, brent at US\$70/b,...) Net debt / EBITDA ~1.5x

* Beyond Bostik and Jurong acquisitions



MAIN STRATEGIC DIRECTIONS





A DIFFERENTIATED STRATEGY BY SEGMENT



* Corporate costs = 0.6% of sales to be deducted from sum of the part



A STRONG AMBITION FOR BOSTIK



Smooth integration

- In a very positive spirit
- Highly committed teams
- Synergies well on track with short-term focus on costs
- Promising start of the year
- Strict benchmarking of competition

2017 objective confirmed

► +30% EBITDA versus 2014 (excluding acquisitions)

Long-term ambition broadened

- ▶ 14 to 15% EBITDA margin ambition confirmed
- x2 EBITDA versus 2014

3 main levers

- Accelerate implementation of strategy focused on emerging countries, global branding, focused innovation, operational excellence
- Bolt-on acquisitions
- Synergies with Arkema in the longer run (acrylics value chain, structural bonding)



SOME MAJOR GROWTH DRIVERS 1/2



* Subject to the exercise of the option to increase our share in Sunke and access a total production capacity of 320kt of acrylic acid per year



SOME MAJOR GROWTH DRIVERS 2/2





2017 EBITDA OBJECTIVE CONFIRMED



Defined in normalized market conditions (Acrylics in mid-cycle, €/US\$ at 1.15, brent at US\$70/b,...) Gearing at ~40%







IMPROVE CASH FLOW GENERATION



* Net cash flow excluding M&A, exceptional capex (such as Kerteh), dividend and cost of hybrid

** Net cash flow / EBITDA



OPERATIONAL EXCELLENCE

TARGET: €100 M GAINS IN 2017 VERSUS 2014



PORTFOLIO OPTIMIZATION



2015-2016

- Integrate and ramp up Bostik and Sunke
- Small bolt-on acquisitions such as Oxido
- January 2016: decision to exercise the option to increase share in Sunke (base case)
- ► 2020 target: bolt-on acquisitions representing a total of €1 bn to €1.5 bn sales post 2017
- 3 priorities to reinforce portfolio
 - Engineering plastics
 - Adhesives
 - Acrylics downstream
- Permanent benchmark with organic growth projects

DIVESTMENTS

- Target to divest €700 m sales of non-core activities between 2015 and 2017
- First step: project to divest Sunclear* (€180 m sales of PMMA distribution)
- ~€500 m sales remaining



DIVIDEND GROWTH SUPPORTED BY PROFIT DEVELOPMENT



The dividend has grown at 14% per year on average since 2007

Arkema has delivered its objective of reaching a 30% payout ratio. The Group aims at maintaining this level on average for the coming years and at paying a stable to growing dividend each year.

A key element of shareholder return



DISCLAIMER

The information disclosed in this document may contain forward-looking statements with respect to the financial condition, results of operations, business and strategy of Arkema. Such statements are based on management's current views and assumptions that could ultimately prove inaccurate and are subject to material risk factors such as among others, changes in raw material prices, currency fluctuations, implementation pace of cost-reduction projects and changes in general economic and business conditions. These risk factors are further developed in the reference document.

Arkema does not assume any liability to update such forward-looking statements whether as a result of any new information or any unexpected event or otherwise. Further information on factors which could affect Arkema's financial results is provided in the documents filed with the French Autorité des marchés financiers.

Financial information for 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006 and 2005 is extracted from the consolidated financial statements of Arkema. Quarterly financial information is not audited.

The business segment information is presented in accordance with Arkema's internal reporting system used by the management.

The definition of the main performance indicators used can be found in the reference document filed with the French *Autorité des Marchés Financiers* and available on www.finance.arkema.com

